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Encouraged by the clinical success of cardiac resynchronization therapy (CRT), the implantation
rate has increased exponentially, although several limitations and unresolved issues of CRT have
been identified. This review concerns issues that are encountered during implantation of CRT
devices, including the role of electroanatomical mapping, whether CRT implantation should
be accompanied by simultaneous atrioventricular nodal ablation in patients with atrial
fibrillation, procedural complications, and when to consider surgical left ventricular lead
positioning. Furthermore, (echocardiographic) CRT optimization and assessment of CRT
benefits after implantation are highlighted. Also, controversial issues such as the potential
value of CRT in patients with mild heart failure or narrow QRS complex are addressed.
Finally, open questions concerning when to combine CRT with implantable cardioverter-
defibrillator therapy and the cost-effectiveness of CRT are discussed. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.0202005;46:2168–82) © 2005 by the American College of Cardiology Foundation
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Mncouraged by the clinical success of cardiac resynchroni-
ation therapy (CRT), the implantation rate of CRT
evices has increased exponentially. However, some limita-
ions and unresolved issues of CRT have been identified.
re-implantation selection of patients who will respond to
RT is still difficult. An extensive review on the issues
efore implantation of a CRT device, mainly focusing on
he issue of identification of responders, is provided in part
of this review (1). In the current manuscript, issues during
mplantation are discussed, including the role of electroana-
omical mapping during implantation to identify the site of
atest activation, whether CRT implantation should be
ccompanied by simultaneous atrioventricular (AV) nodal
blation in patients with atrial fibrillation (AF), procedural
omplications, and when to consider surgical left ventricular
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lantation are discussed, including (echocardiographic)
RT optimization and assessment of CRT benefits. Fi-
ally, many issues are still unclear in CRT, including the
otential value in mild heart failure or in patients with
arrow QRS complexes, when CRT should be accompanied
y an ICD, and cost-effectiveness of the therapy; these
ssues are also addressed.
SSUES DURING CRT IMPLANTATION
ole of electroanatomical mapping in CRT. In normal
ndividuals, electrical activation of both ventricles is pre-
eded by depolarization of the His-Purkinje system result-
ng in rapid activation of both ventricles with only a short
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December 20, 2005:2168–82 Issues During and After Device Implantationelay in activation between the earliest and the latest
ctivated segments (2). In patients with left bundle branch
lock (LBBB), the total activation of the LV is prolonged
ith delayed activation and contraction of the lateral wall.
owever, even in the presence of LBBB, endocardial
ctivation may be prolonged only minimally (2). In these
atients, LBBB morphology could primarily be caused by
elayed intramural activation (3). Consequently, it was
emonstrated that although QRS duration showed a con-
inuous distribution, there was binary distribution of trans-
eptal activation times supporting the concept of two
ifferent forms of LV activation in the presence of LBBB on
he electrocardiogram (ECG). The first entity is character-
zed by a relatively short trans-septal time (20 ms)
ndicating intact His-Purkinje activation, whereas the sec-
nd entity is characterized by a longer trans-septal activation
ime (40 ms) indicating “cell-to-cell” activation from right
entricle (RV) to LV (3). Both mechanisms of delayed LV
ctivation may result in an intraventricular mechanical delay
f the LV, which can be analyzed in detail with tissue
oppler imaging (TDI) and electroanatomical mapping.
he use of electromechanical mapping to assess intraven-
ricular and intramural dyssynchrony has been reported (3).
f interest, three-dimensional mapping studies revealed the
resence of long lines of block or slow conduction in heart
ailure with LBBB (Fig. 1) (2–4). The location and length
f these lines of conduction block were highly variable, with
elayed activation of different parts of the lateral wall of the
V. Moreover, the location of these lines of block was not
xed and could change, suggesting that they were (at least in
art) functionally determined rather than related to areas of
car tissue. By comparing uni- and bipolar recordings, the
onduction delay within these lines of block could be located
n the subendocardium or could be intramural in origin (3).
he exact nature of the intramural conduction delay is not
Abbreviations and Acronyms
AF  atrial fibrillation
AV  atrioventricular
COMPANION  Comparison of Medical Therapy,
Pacing and Defibrillation in Heart
Failure
CRT  cardiac resynchronization therapy
ICD  implantable cardioverter-defibrillator
LBBB  left bundle branch block
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
MR  mitral regurgitation
MUSTIC  Multisite Simulation in
Cardiomyopathies trial
NYHA  New York Heart Association
PET  positron emission tomography
QALY  quality adjusted life year
RV  right ventricle/ventricular
TDI  tissue Doppler imaging
VV  interventricularntirely clear. As a consequence of the presence of long lines df conduction block, a “U” shaped activation pattern was
ften observed in patients with LBBB. The activation wave
ront turns around the LV apex and inferior wall in order to
ctivate the lateral wall. Furthermore, as the activation
equence behind the line of block developed from the apical
o the basal part of the lateral wall, the basal part is activated
ast. It has been hypothesized (3) that absence of these lines
f block may preclude CRT benefit (Fig. 2). One of the
roposed mechanisms underlying response to CRT in patients
ith heart failure and LBBB is pre-excitation of the most
elayed LV segment, thereby reducing LV dyssynchrony and
estoring coordinated contraction. It is reasonable to postu-
ate that, in order to correct electrical dyssynchrony, LV
acing sites should be located lateral to the lines of conduc-
ion block (Fig. 1). Positioning of the pacing lead on the
wrong” site of the line of block may even result in an
ncrease of dyssynchrony (the activation wave front has to
omplete a full U-turn in that case). Furthermore, because
he basal part of the LV is activated last, it is tempting to
peculate that the LV pacing lead should be positioned near
he most basal segments. Currently, however, no studies are
vailable to substantiate this hypothesis.
V lead positioning: transvenous or surgical? Left ven-
ricular lead placement is usually performed by a trans-
enous approach using the tributaries of the coronary sinus.
ntubation of the coronary sinus with a dedicated guiding
atheter facilitates LV lead implantation by providing sup-
ort for advancing the pacing leads and allowing exchange
f the angiography catheter and different pacing leads in
ifficult cases. Optimal projection for identifying the ostium
s the left anterior oblique projection, but the right anterior
blique view may aid in defining the angulation of side-
ranch take-offs. A “conventional” stylet-guided pacing lead
r an “over-the-wire” approach may be used. For the latter,
guidewire is first advanced into the desired branch then
ollowed by the lead that has a central lumen. The “over-
he-wire” technique is preferred for small tortuous veins,
hereas conventional leads may provide superior stability in
arge veins with a relatively straight course; fixation is usually
assive (anchors or pre-shaped curves). The feasibility of
ransvenous lead positioning is determined by anatomical
nd technical factors including venous anatomy, accessibility
f the vein, pacing threshold, lead stability, and absence of
hrenic nerve stimulation. With state-of-the art lead tech-
ology, the ability to access specific coronary veins is not
sually problematic. Venous anatomy can be evaluated
uring the procedure by retrograde venography but is also
ossible with non-invasive imaging using multislice com-
uted tomography (5). The precise incidence of suitable
eins for CRT is not known and may differ between patients
ith ischemic and non-ischemic cardiomyopathy. Still,
eisel et al. (6) have shown that 55% of patients have
uitable posterior veins, whereas 99% have posterior or left
arginal veins. Implant failures are more often due to
nlargement of the right atrium and the accompanying
istortion of the coronary sinus ostium leading to inability
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Issues During and After Device Implantation December 20, 2005:2168–82o cannulate the ostium (up to 4%) or insufficient support by
he guiding catheter (6). A steerable electrophysiology
atheter can be used inside the guiding catheter to facilitate
oronary sinus intubation. A myocardial pacing threshold
2 V is acceptable, but phrenic nerve stimulation should be
bsent even at high output. Overall, implant success rates
90% can be achieved in experienced centers.
The main procedural complications include lead dis-
odgement, coronary sinus dissection, and phrenic nerve
timulation. Lead dislodgement occurred in 6% of the
atients in the Cardiac Resynchronization-Heart Failure
CARE-HF) trial, in 4% in the Multicenter InSync Random-
zed Clinical Evaluation (MIRACLE) trial, and in 12% in the
ultisite Simulation in Cardiomyopathies (MUSTIC) trial
7–9). Coronary sinus dissection has been reported in about
.4% to 4% of patients (10); healing is usually uncompli-
ated, and vessel perforation is uncommon. In most in-
tances, LV lead implantation can safely be performed
everal weeks after a dissection.
Phrenic nerve stimulation has been noted chronically in
.6% to 12% of patients (11) and should therefore be
igure 1. (Top) Ventricular activation sequence using three-dimension
innesota) in a patient with dilated (non-ischemic) cardiomyopathy (le
NYHA] functional class III) with a QRS duration of 154 ms who responde
hen encountering a conduction block located at the LV anterior wall, resu
ver the line of block are displayed. Note the fragmented or double poten
white arrow, top). One year after CRT, the LVEF was 42%, and the passessed during the implant procedure. Still, phrenic nerve stimulation may occur de novo during follow-up due to
hanges in body position. Adjustment of pacing output or
sing other pacing configurations can often resolve this
ituation, but occasionally lead repositioning is required.
Although lead positioning is limited by anatomical and
echnical factors, the aim is to resynchronize the LV. With
urrent echocardiographic techniques, including TDI and
issue synchronization imaging, it is possible to precisely
ocate (before device implantation) the site of latest activa-
ion. In general, the site of latest activation is located in the
osterolateral region. In a relatively early study, investigators
emonstrated that benefit from CRT was significantly
reater when the lateral wall was paced as compared to the
nterior wall (12); TDI was not used to assess the site of
atest activation in this study. A later study confirmed with
DI that the site of latest activation was located in the
nferior or posterolateral regions in 75% of patients under-
oing CRT (13).
Integration of TDI to assess the site of latest activation
nd visualization of venous anatomy will allow determina-
ion of the feasibility of a transvenous approach. When the
ncontact mapping (EnSite 3000, Endocardial Solutions, Minneapolis,
tricular [LV] ejection fraction [EF] 30%, New York Heart Association
ardiac resynchronization therapy (CRT). The propagation wavefront splits
in delayed activation of the lateral wall. (Bottom) The virtual electrograms
ectrograms. The LV lead was positioned at the basal lateral region of LV
was in NYHA functional class I. LAT  lateral.al no
ft ven
d to c
ltingite of latest activation is not in the region of suitable veins,
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December 20, 2005:2168–82 Issues During and After Device Implantationurgical LV lead positioning may be considered, using
imited left-lateral thoracotomy with direct epicardial lead
lacement (14). There is no data from large trials on surgical
V lead placement. Mair et al. (15) compared 16 patients
ndergoing surgical lead placement with 63 patients under-
oing transvenous lead placement; the authors reported a
ower incidence of procedural-related events with the sur-
ical approach. Koos et al. (14) evaluated 81 patients
ndergoing CRT, with 25 having a surgical approach for
V lead positioning. A lower incidence of re-interventions
as observed after surgical LV lead positioning; however,
ospitalization was longer, and clinical benefit was smaller
lesser LV reverse remodeling, less increase in LV ejection
raction [EF] and peak O2) as compared to transvenous lead
ositioning. With surgery, the LV leads were more often
ositioned anteriorly (44% vs. 4.5% with the transvenous
pproach), and this position may not be ideal for LV
esynchronization. More data on surgical LV lead implan-
ation are needed.
RT in chronic AF. Chronic AF occurs frequently in
atients with end-stage heart failure. The prevalence of AF
as been reported to increase in parallel to the severity of
igure 2. (Top) Ventricular activation sequence (right anterior obliqu
ndocardial Solutions) in a patient with ischemic cardiomyopathy (left vent
lass III) with a QRS duration of 148 ms who did not respond to cardia
posterior view [POST]). There was no line of block or acute change in p
ystem. Of note, there were differences in the electrocardiogram (ECG) pa
he surface ECG fails to predict the activation sequences in these patients
low conduction velocity in the myocardium. The LV lead was positioned
linical status of the patient unchanged.eart failure, with 10% to 15% of patients in New York beart Association (NYHA) functional class II to III and up
o 50% of patients in NYHA class IV having AF (16).
onsidering the high prevalence of AF in patients with
evere heart failure, it is noteworthy that all major trials
eported on patients with sinus rhythm, which may not be
n adequate reflection of the heart failure population. If
RT is considered in patients with chronic AF, it is
ssential that rapid intrinsic AV nodal conduction does not
nhibit resynchronization therapy. This is at times accom-
lished by performing an AV nodal ablation. At present, no
ontrolled, randomized studies are available to support this
ypothesis.
The limited available evidence suggests a beneficial effect
f CRT in patients with chronic AF. Initial studies have
ocused on the acute effect of CRT on hemodynamic
arameters in patients with AF. Several single-center stud-
es with relatively small numbers of patients have been
eported (17,18) and demonstrated acute hemodynamic
mprovement in patients with chronic AF receiving CRT.
he available evidence on the long-term effects of CRT in
atients with heart failure and chronic AF is also scarce. As
llustrated in Table 1, the effects of CRT (with follow-up
[Ant]) using three-dimensional noncontact mapping (EnSite 3000,
r [LV] ejection fraction [EF] 35%, New York Heart Association functional
nchronization therapy (CRT). (Bottom) Ventricular activation sequence
ation direction of the depolarization wavefront detected by the mapping
between this patient and the patient displayed in Figure 1, indicating that
prolonged LV activation time in this patient may be due to the relatively
e posterolateral vein. One year after CRT, the LVEF was 34% and thee view
ricula
c resy
ropag
ttern
. Theetween 3 and 14 months) were evaluated in a total of 124
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Issues During and After Device Implantation December 20, 2005:2168–82atients with AF, ranging from 15 to 59 patients per study.
n the majority of these four studies, however, an improvement
n NYHA functional class, 6-min walking distance, and
uality-of-life score was shown, associated with improvement
n LVEF. In single-center studies, improvement in addi-
ional echocardiographic parameters has been shown (19).
Two studies reported on the comparison of benefit from
RT in patients with AF as compared to patients with sinus
hythm (20,21), and demonstrated comparable benefit of
RT in both groups. On an individual basis, however, the
able 1. CRT in Randomized Clinical Trials
Trials Design Patients (n) Pr
ATH-CHF (1) Crossover 41 6MWT
Peak VO2
USTIC-SR (2) Crossover 58 6MWT
IRACLE (3) Parallel arms 453 6MWT
NYHA fu
QOL
IRACLE-ICD (4) Parallel arms 555 6MWT
NYHA fu
QOL
OMPANION (5) Parallel arms 1,520 All-cause
hospital
ARE-HF (6) Open label,
randomized
814 All-cause
ATH-CHF II (7) Crossover (no
pacing vs. LV
pacing)
86 6MWT
Peak VO2
ONTAK-CD (8) Crossover, parallel
controlled
490 6MWT
NYHA fu
QOL
ARE-HF  Cardiac Resynchronization-Heart Failure; CONTAK-CD  CONTA
efibrillation in Heart Failure; CRT  cardiac resynchronization therapy; LV  left
jection fraction; LVESV  left ventricular end-systolic volume; MIRACLE 
mplantable Cardioverter Defibrillator trial; MR  mitral regurgitation; MUSTIC
ATH-CHF  Pacing Therapies in Congestive Heart Failure trial; QOL  qualit
achycardia; 6-MWT  6-min walk test.linical response rate was significantly higher in the patients (ith sinus rhythm as compared to AF (Fig. 3) (21). This
ifference may be (partially) due to the relatively low
esponse rate in the patients with AF who did not undergo
V nodal ablation, as compared to those who underwent
blation (54% vs. 71%) (21).
To date, only one prospective, randomized, and con-
rolled trial designed to assess the efficacy of CRT in AF
atients with severe heart failure has been published (22). In
he MUSTIC AF trial (22,23), 59 patients with end-stage
eart failure and permanent AF, LVEF 35%, and wide
End Points
Results SummarySecondary
NYHA functional class
QOL
Hospitalizations
Improvement in
6MWT
NYHA functional class
QOL
Less hospitalizations
NYHA functional class
QOL
Peak VO2
LV volumes
MR
Hospitalizations
Total mortality
Improvement in
6MWT
NYHA functional class
QOL
Peak VO2
LV volumes
MR
Less hospitalizations
nal class
Peak VO2
LVEF
LVEDD
MR
Clinical composite response
Improvement in
6MWT
NYHA functional class
QOL
LVEF
LVEDD
MR
nal class
Peak VO2
LVEF
LV volumes
MR
Clinical composite response
Improvement in
NYHA functional class
QOL
lity or
n
All-cause mortality and
cardiac morbidity
Reduced all-cause mortality/
hospitalization
lity NYHA functional class
QOL
LVEF
LVESV
Hospitalization for heart
failure
Reduced mortality/morbidity
Improvement in
NYHA functional class
QOL
LVEF
LVESV
NYHA functional class
QOL
Improvement in
6MWT
QOL
Peak VO2
nal class
LVEF
LV volumes
Composite of mortality,
hospitalizations, VT/VF
Improvement in
6MWT
NYHA functional class
QOL
LVEF
LV volumes
rdiac Defibrillator; COMPANION  Comparison of Medical Therapy, Pacing and
icular; LVEDD  left ventricular end-diastolic dimension; LVEF  left ventricular
enter InSync Randomized Clinical Evaluation; MIRACLE-ICD  MIRACLE
ultisite Simulation in Cardiomyopathics; NYHA  New York Heart Association;
fe score; VF  ventricular fibrillation; VO2  volume of oxygen; VT  ventricularimary
nctio
nctio
morta
izatio
morta
nctio
K-Ca
ventr
Multic
 MRV-paced) QRS complex were randomized for two periods
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December 20, 2005:2168–82 Issues During and After Device Implantationf three months (conventional RV pacing or CRT). In
atients with effective therapy (i.e., CRT for 85% of
ime), a significant improvement was observed in NYHA
unctional class, 6-min walking distance, and quality-of-life
core. In addition, LV reverse remodeling was observed
ith a reduction in hospitalization rate for heart failure.
inde et al. (23) subsequently demonstrated that benefit of
RT was sustained at 12 months.
From the limited data (Table 1), it appears that CRT is
ffective in patients with chronic AF, although larger studies
re needed to confirm the findings. An important issue
emains whether CRT in chronic AF patients should be
ccompanied with AV nodal ablation, and, although anec-
otal data support this concept, more substantial data are
eeded. A theoretical argument against AV nodal ablation
s the hypothesis that CRT results in reverse LV remodel-
ng, with reduction of mitral regurgitation (MR), and that
inus rhythm may be restored spontaneously over time
uring CRT. However, no solid data exist on the incidence
f spontaneous restoration of sinus rhythm in AF patients
ndergoing CRT.
SSUES AFTER CRT IMPLANTATION
ptimization of AV and interventricular (VV) delays in
RT. Optimization of pacemaker settings may further
nhance benefit from CRT. Both AV and VV delay can be
ptimized with contemporary CRT devices. The aim of AV
elay optimization is to avoid LV systolic contraction taking
lace after suboptimal LV filling. In an early study (24) in
5 patients with heart failure and severely depressed LV
unction who underwent dual-chamber (atrial synchronized
V) pacing, AV delay optimization substantially increased
ardiac output. The AV delay was optimized using Doppler
chocardiography, and benefit was validated by invasive
easurements including cardiac output. An optimal AV
elay was programmed when the end of the “Doppler
-wave” (corresponding to left atrial contraction) occurred
ust before the onset of aortic systolic Doppler flow. This
chocardiography-guided AV optimization appeared crucial
igure 3. The incidence of responders to cardiac resynchronization therapy
n patients with sinus rhythm (left) is higher than in patients with atrial
brillation (right) (data based on reference 21). Black  non-responders;
hite  responders.n some heart failure patients who exhibited an increase in fiardiac output by 50%. Unfortunately, the LV systolic
ctivation sequence remained delayed and heterogeneous
ecause pacing was performed via the RV apex, not using
he highly differentiated Purkinje tissue. Cardiac resynchro-
ization therapy now allows stimulation of both ventricles
imultaneously, which reduces the aortic pre-ejection time
nterval (25,26) making re-optimization of the timing be-
ween the end of the “Doppler A-wave” and the onset of the
ortic systolic flow necessary (Fig. 4). Auricchio et al. (27)
ave shown that quality of LV filling determined optimal
V ejection. The authors studied 27 patients and evaluated
he acute effect of different AV delays on maximum LV
ressure derivative and aortic pulse pressure, and demon-
trated individual AV optimization yielded optimal im-
rovements in hemodynamic measurements. These obser-
ations indicate that the AV delay needs to be evaluated on
patient basis instead using generalized settings. Still,
vidence is needed on the beneficial effect of AV delay
ptimization during long-term follow-up.
The recent generation of CRT devices also allows for
ptimization of VV delay (28–31). Sogaard et al. (29) were
he first to demonstrate additional benefit of sequential
entricular pacing over simultaneous CRT. The authors
emonstrated an immediate reduction in LV dyssynchrony
assessed by tissue tracking) after onset of CRT (with
imultaneous RV and LV pacing), resulting in an increased
VEF (from 22 6% to 30 5%, p 0.01). Optimization
f VV delay induced a further reduction in LV dyssyn-
hrony with an additional increase in LVEF (to 34  6%,
 0.01). Other investigators (30) demonstrated a
ignificant reduction in MR after CRT with simulta-
eous ventricular pacing, with a further reduction after
V optimization (Fig. 5). Thus, the benefit of sequential
RT with an individually optimized VV delay is related to
n increased diastolic filling time with a reduction in LV
yssynchrony, leading to a better systolic performance with
ore synchronous motion of the mitral leaflets, thereby
educing MR.
Recent observations suggest that the optimal sequence of
entricular pacing varies substantially between patients.
orciani et al. (31) demonstrated that 50% of patients
howed most benefit from LV pre-activation, whereas the
ther 50% had most benefit from RV pre-activation, illus-
rating the need for a patient-tailored approach to optimize
acemaker settings. The definition of an optimal VV delay
as not yet been fully characterized and could reflect the VV
nterval that yields a maximal reduction in LV dyssynchrony
nd/or a maximal increase in LV systolic function. In daily
ractice, echocardiographic assessment of cardiac output
sing the LV outflow (aortic velocity-time integral) at
ifferent VV intervals may be the preferred approach to
ssess optimal VV settings. It should be emphasized, how-
ver, that long-term benefit of sequential over simultaneous
entricular pacing has not yet been demonstrated. In addi-
ion, the sequence of AV and VV optimization (i.e., which
rst and which second) is also not yet clear.
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Issues During and After Device Implantation December 20, 2005:2168–82hat benefit can be measured acutely and chronically
fter CRT? The effects of CRT can be divided into acute
nd chronic effects (Table 2). Studies in the acute setting
ave demonstrated that CRT abruptly enhances LV systolic
unction. In both experimental and clinical studies, this is
anifest by a modest (6 mm Hg) rise in systolic pressure
27,32), increase in stroke volume (10% to 30%) (32),
eduction in the LV end-systolic volume and, thus, LV
nd-systolic stress, and a more rapid rise of LV pressure
dP/dtmax, between 15% to 35%) (27,32,33). There is also
mproved cardiac work at similar or lower oxygen con-
umption (34) so that chamber energetic efficiency is
mproved. Many of these changes can be observed within
single beat upon activating CRT, and are sustained in
igure 4. Consequences of optimization of atrioventricular (AV) delay du
1 is wide due to apical right ventricular pacing (165 ms). The aortic pre-e
o the wide QRS complex. The second QRS complex resulting from P2 is n
nterval (Pre-Ao2) compared with Pre-Ao1. Consequently, time duration o
arlier (compared to P1 and P2) with a greater amplitude, indicating a bet
f an AV delay optimization during P3, resulting in a greater cardiac o
iventricular pacing was delivered without AV delay optimization.
igure 5. Changes in mitral regurgitation according to different pacing m
imultaneous biventricular pacing, showing significant reduction in mitral regu
acing with optimized interventricular delay (left ventricular pre-activation of 2he short-term studies until CRT is abruptly terminated
here they are rapidly reversed. The impact of CRT on
iastolic function remains somewhat less clear. Acute
tudies have rarely shown significant effects on relaxation
ime constant, and there is no demonstrable effect on
hamber stiffness (32).
Chronic CRT triggers similar changes in a number of
emodynamic parameters, but also results in reversal of LV
ilation. Echocardiographic studies have shown 10% de-
lines in LV end-systolic and end-diastolic volumes, asso-
iated with an increase in LVEF (35–37).
ffect of CRT on MR. A significant reduction in MR has
lso been reported after CRT. Some patients exhibit imme-
iate reduction in MR, whereas other patients show im-
iventricular pacing at stable heart rate. The QRS complex resulting from
n time interval (Pre-Ao1) is long; the aortic systolic phase is also long due
ed due to biventricular pacing leading to a shorter aortic pre-ejection time
ortic systolic phase is reduced, and the E-wave corresponding to P3 occurs
filling phase. Pre-Ao3 is even shorter than Pre-Ao2 due to the addition
(CO) during P3 compared with the one obtained during P2, in which
(A) Spontaneous sinus rhythm showing severe mitral regurgitation. (B)ring b
jectio
arrow
f the a
ter LVodes.
rgitation. (C) Further reduction of mitral regurgitation after biventricular
0 ms).
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December 20, 2005:2168–82 Issues During and After Device Implantationrovement only late after CRT. This is related to the
nderlying pathophysiology of MR in end-stage heart
ailure. The LV dilation results in systolic retraction of the
apillary muscles towards the apex, which inhibits complete
eaflet coaptation in particular in the presence of a simulta-
eous decrease in the systolic closing force (38). In addition,
all motion abnormalities in the inferior/posterior regions
an result in papillary muscle dysfunction with subsequent
R (39); LV dyssynchrony does also contribute to MR
40). A prolonged AV interval delays the onset of LV
ontraction and predisposes to incomplete mitral valve
losure with the occurrence of pre-systolic (diastolic) MR
41). The resulting LV volume overload contributes further
o the progressive deterioration in LV function, which in
urn again increases MR (42). The pre-systolic component
f MR can be effectively eliminated by pacing with a short
optimized) AV delay, while the CRT-related immediate
eduction in the degree of systolic MR is associated with an
cute hemodynamic improvement. Breithardt et al. (43)
tudied patients during brief re-programming of a CRT
evice and quantified the changes in the extent of MR with
chocardiography by the proximal isovelocity surface area
ethod. The changes in MR severity were compared to the
hanges in LV systolic function (LV peak positive rate of
ressure rise, LV dP/dtmax), measured noninvasively by
oppler echocardiography. A linear correlation between the
ffective regurgitant orifice area and LV dP/dtmax was
bserved, and it was concluded that an improved transmitral
ressure gradient (the closing force on the mitral leaflet)
educes MR severity by earlier and more effective mitral
eaflet closure. An example of an acute reduction in MR
fter onset of CRT is demonstrated in Figure 6. Kanzaki et
l. (44) confirmed these findings and added data on the role
f papillary muscle resynchronization during CRT. The
uthors studied the deformation sequence of the papillary
uscles by strain rate imaging and reported a direct rela-
ionship between the interpapillary muscle activation time
elay and the improvement in the degree of MR by CRT.
hus, the immediate reduction in MR severity can be
ttributed to an improved coordination of ventricular con-
raction, including resynchronized papillary muscle activa-
ion, which results in improved systolic function and re-
uced mitral leaflet tethering forces. This effect can be
able 2. Early and Late Effects After CRT
Acute Changes Chronic Changes
Systolic pressure 1 Systolic pressure
Stroke volume 2 End-systolic volume
End-systolic volume 2 End-diastolic volume
Cardiac energetic efficiency 1 Ejection fraction
Arterial pulse pressure 1 Arterial pulse pressure
dP/dtmax 1 dP/dtmax
or ↔ Relaxation time ↔ Relaxation time
Diastolic compliance Reverse remodeling
RT  cardiac resynchronization therapy; dP/dtmax  change in left ventricular
ressure over time.bserved in patients with ischemic and non-ischemic car- aiomyopathy (36). Effective CRT immediately reduced the
ransmitral regurgitant volume at rest by about 30% to 40%
n average (35,43,44). A further 10% to 20% improvement
an be observed after some months of CRT and is probably
elated to the LV reverse remodeling (35).
ffect of CRT on quantitative blood flow and metabo-
ism. Various studies have evaluated the effect of CRT on
yocardial perfusion and metabolism. In order to assess
mall differences in a quantitative manner, positron emission
omography (PET) was used. In mild heart failure, LV
fficiency of forward work is reduced, whereas RV oxidative
etabolism is increased (probably due to an increased
ressure load) (45). Resting perfusion may be normal, but
he perfusion reserve is typically reduced. With more severe
eart failure, LV oxidative metabolism becomes also com-
romised (46). In addition to the effects of heart failure per
e, commonly coexisting LBBB leads to striking regional
eterogeneity in perfusion and oxidative metabolism. In
articular, perfusion and metabolism are reduced in the VV
eptum and increased in the lateral wall. The various PET
tudies that have evaluated the effect of CRT on myocardial
lood flow and metabolism are summarized in Table 3. It
hould be noted that the total number of patients (n  99)
tudied with PET is still limited, and the number or patients
er study is also small (ranging from 6 to 14) (47–55). The
vailable evidence indicates that CRT does not increase
esting myocardial blood flow (Table 3, Fig. 7). The
vidence on flow reserve is minimal. Knaapen et al. (54)
tudied 14 patients with PET and O15-labeled water and
emonstrated a significant increase in flow reserve after
RT; conversely, Sundell et al. (50) also studied 10 patients
ith PET and O15-labeled water and demonstrated no
hange in flow reserve. Clearly, more information is needed
n this topic.
Myocardial glucose utilization was evaluated in two
tudies, demonstrating that glucose uptake in the VV
eptum increased significantly after CRT (47,53).
In addition, three studies evaluated LV oxidative metab-
lism using PET and C11 acetate before and after CRT
48,50,51). These studies uniformly demonstrated no
hange in global LV oxidative metabolism, although an
mprovement in systolic LV function was demonstrated.
he studies were also consistent in demonstrating increased
yocardial efficiency, indicating improved oxygen cost of
orward work by CRT (Table 3, Fig. 8). These studies
onfirm the earlier work by Nelson et al. (34) who demon-
trated in an invasive setting that CRT improved systolic
unction with a reduction in energy cost. The PET studies
lso showed that oxidative metabolism became more ho-
ogenous throughout the LV. Similar to glucose utiliza-
ion, CRT appears to enhance oxidative metabolism in the
V septum with a simultaneous reduction in the lateral
all. This observation suggests a more balanced wall stressnd energy requirements during CRT.
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RT in NYHA class II heart failure. It has been hypoth-
sized that patients with mild heart failure (i.e., NYHA
unctional class II) may also benefit from CRT, not so much
s a therapy for heart failure, but rather to prevent devel-
pment of heart failure. Thus far, one double-blind,
arallel-controlled study focused on the effects of CRT in
atients with NYHA functional class II heart failure and a
lassic indication for an implantable cardioverter-
efibrillator (ICD) (56). These patients did not improve
but also did not worsen) in quality-of-life score and exercise
olerance, but significant reverse LV remodeling was ob-
erved. Another CRT study suggested improvement in
linical parameters in NYHA functional class II heart
ailure patients (57). To further substantiate these findings,
ontrolled studies are needed. The REsynchronization re-
Erses Remodeling in Systolic left vEntricular dysfunction
REVERSE) trial is an ongoing prospective, randomized,
ouble-blind parallel study, designed to assess whether
RT combined with optimized medical therapy can atten-
ate progression of heart failure over at least 12 months, as
ompared to optimized medical treatment alone. Approxi-
ately 500 patients with either asymptomatic LV dysfunc-
ion or mild (NYHA functional class II) heart failure, QRS
uration 120 ms, LVEF 40%, and LV end-diastolic
igure 6. Immediate effect of cardiac resynchronization therapy (CRT) o
hows moderate mitral regurgitation during no pacing (CRT OFF, A) and
). During CRT, the mitral regurgitant jet is smaller, corresponding to m
dP/dt by continuous-wave Doppler echocardiography has improved signiameter 55 mm will be included and followed-up for five Mears. The primary end point is the clinical composite end
oint, with LV end-systolic volume index as the first-order
econdary end point.
RT in narrow QRS complex. The value of CRT in heart
ailure patients with narrow QRS complex has not been
esolved. Assuming that LV dyssynchrony is the main
eterminant of response to CRT, these patients need to be
creened with advanced echocardiographic techniques (58).
wo studies evaluated the incidence of LV dyssynchrony in
atients with narrow QRS complex (59,60). Yu et al. (59)
valuated 67 patients with narrow QRS complex (120 ms,
verage 99  11 ms) and heart failure with TDI and
emonstrated LV dyssynchrony in 43% of patients. An
xample of a patient with LV dyssynchrony is presented in
igure 9. Bleeker et al. (60) showed a somewhat lower
ncidence (27%) of LV dyssynchrony (Fig. 10), which may
ave been related to patient characteristics or to a slightly
ifferent analysis of data and definition of LV dyssynchrony.
hus far, two small studies have shown actual benefit from
RT in patients with severe heart failure, depressed LVEF,
nd narrow QRS complex with LV dyssynchrony on echo-
ardiography (61,62). In a study of 14 patients with QRS
uration 120 ms, an improvement in NYHA functional
lass, 6-min walking distance and LVEF, with reverse LV
emodeling were noted after six months of CRT (61).
severity of mitral regurgitation. Color-coded Doppler echocardiography
stimated left ventricular (LV)peak dP/dt is 361 mm Hg/s (CRT OFF,
itral regurgitation (CRT ON, C). The simultaneously acquired LVpeak
tly to 823 mm Hg/s (CRT ON, D).n the
the eoreover, it was demonstrated that the magnitude of
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December 20, 2005:2168–82 Issues During and After Device Implantationmprovement in clinical parameters after CRT was similar
n a comparable group of patients with wide QRS complex.
hould CRT be combined with ICD back-up? Heart
ailure has a poor prognosis with a five-year mortality of
pproximately 50% (63); cardiac mortality is high, and mode
f death appears related to severity of heart failure. Patients
ith severe heart failure die more frequently of worsening
able 3. Summary of the Available Studies Using PET to Assess
Study
Study
Population Measured PET Pa
eri et al. (47) 8
100% DCM
LVEF 27  12%
Resting MBF (N13
Glucose uptake (F18
kkonen et al. (48) 8
25% DCM
LVEF 26  9%
MVO2 rest (C11 ace
ielsen et al. (49) 14
36% DCM
LVEF 21  5%
Resting MBF (N13
undell et al. (50) 10
100% DCM
LVEF 32  8%
MBF at rest/during
MVO2 at rest/during
raunschweig et al. (51) 6
50% DCM
LVEF 22  9%
MBF at rest/during
MVO2 at rest/during
owak et al. (52) 14
100% DCM
LVEF 23  13%
Resting MBF (O15
owak et al. (53) 15
100% DCM
LVEF 22  12%
Glucose uptake (F18
naapen et al. (54) 14
57% DCM
LVEF 25  7%
MBF at rest/during
nuuti et al. (55) 10
100% DCM
LVEF 32  8%
RV MVO2 at rest/d
(O15 water)
RT  cardiac resynchronization therapy; DCM  idiopathic dilated cardiomyopa
lood flow; MVO2  myocardial oxygen consumption; PET  positron emission to
igure 7. Cardiac resynchronization therapy (CRT) appears to have no
ffect on basal (resting) blood flow (measured quantitatively by positron
mission tomography using O15-labeled water) (left) or blood flow reserve
measured after adenosine vasodilation, right). (Data based on reference
0).
d
reart failure, and patients with mild-to-moderate heart
ailure have a higher incidence of sudden death. Still, in
bsolute numbers, the sudden death rate is high even in
atients with NYHA functional class III or IV heart failure
59% and 33% of all deaths, respectively) (63). Improving
urvival in these patients should focus on treatment of heart
ailure and prevention of sudden death; CRT has been
emonstrated in large trials to improve heart failure symp-
ct of CRT on Myocardial Blood Flow and Metabolism
ters (Radionuclides) Main Findings: CRT ON Versus OFF
onia)
yglucose)
No effect on MBF
Septal glucose uptake increased
LV and RV global MVO2 unchanged
Myocardial efficiency improved
Septal to lateral wall ratio of MVO2 increased
onia) No effect on global and regional MBF
sine (O15 water)
tamine (C11 acetate)
No effect on global and regional MBF
No effect on global and regional flow reserve
LV global MVO2 unchanged
Myocardial efficiency improved
Stress (dobutamine) MVO2 enhanced
tamine (C11 acetate)
tamine (C11 acetate)
No effect on resting MBF/flow reserve
No effect on resting MVO2
Stress (dobutamine) MVO2 enhanced
) No effect on global and regional MBF
yglucose) Septal glucose uptake increased
sine (O15 water) No effect on global MBF but regional MBF
became more homogeneous
Global hyperemic MBF increased
Global flow reserve increased
dobutamine No effect on resting MVO2 in RV
Stress MVO2 enhanced in RV
Subjects with high MVO2 in RV were
functionally non-responders
V  left ventricular; LVEF  left ventricular ejection fraction; MBF  myocardial
phy; RV  right ventricular.
igure 8. Cardiac resynchronization therapy (CRT) significantly increased
asal myocardial efficiency (based on assessment by positron emission
omography using C11 acetate) (left), and a similar trend was observedEffe
rame
amm
deox
tate)
amm
adeno
dobu
dobu
dobu
water
deox
adeno
uringuring dobutamine stress (although not significant, right). (Data based on
eference 50). Open bars  CRT on; solid bars  CRT off.
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Issues During and After Device Implantation December 20, 2005:2168–82igure 9. Tissue Doppler imaging in a patient with heart failure and narrow QRS complex, showing left ventricular (LV) dyssynchrony in multiple
egments (top, middle, and bottom panels) as illustrated by the temporal difference in peak systolic velocity during the ejection phase (arrows). (Top)
issue Doppler imaging velocity tracings obtained in the interventricular septum (yellow and light blue curves) and lateral wall (red and green curves).
arliest activation (peak systolic velocities, first arrow) is in the septum, and latest activation in the lateral wall (peak systolic velocities, second arrow). Thus,
ignificant LV dyssynchrony is present between the septum and the lateral wall. (Middle) Tissue Doppler imaging velocity tracings obtained in the anterior
all (red and green curves) and inferior wall (yellow and light blue curves). Earliest activation (peak systolic velocities, first arrow) is in the anterior wall,
nd latest activation in the inferior wall (peak systolic velocities, second arrow). Thus, significant LV dyssynchrony exists between the anterior and inferior
all. (Bottom) Tissue Doppler imaging velocity tracings obtained in the anteroseptal wall (red and green curves) and posterior (yellow and light blue
urves). Earliest activation (peak systolic velocities, first arrow) is in the anteroseptal wall, and latest activation in the posterior wall (peak systolic velocities,
econd arrow). Thus, significant LV dyssynchrony is present between the anteroseptal and posterior wall. AVC  aortic valve closure; AVO  aortic valve
pening.
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December 20, 2005:2168–82 Issues During and After Device Implantationoms and LV systolic function. The effect was larger than
hat obtained with optimized medical therapy (7,8,10), and
any patients improved from NYHA functional class III or
V to I or II after CRT (7,8,10). Moreover, results from the
ARE-HF study demonstrated a reduced two-year mor-
ality rate with CRT as compared to optimized medical
herapy (18% vs. 25.1%) (7). Detailed analysis on the mode
f death revealed that 47% of deaths in the medical-therapy
roup could be attributed to worsening heart failure as
ompared to 40% in the CRT group. Moreover, 32% of
eaths in the medical-therapy group were attributed to
udden cardiac death as compared to 35% in the CRT
roup.
Implantable cardioverter defibrillator therapy is the opti-
al therapy to prevent sudden death; efficacy of ICD
herapy is well established in both secondary and primary
revention trials (64–66). Currently, the Comparison of
edical Therapy, Pacing and Defibrillation in Heart Fail-
re (COMPANION) trial is the only randomized study
valuating whether CRT with or without ICD back-up
ould reduce all-cause mortality and hospitalization com-
ared to optimized medical therapy (10). Patients were
andomly assigned to optimized medical therapy (20%),
RT therapy (40%), and CRT ICD back-up (40%). This
rial was terminated after inclusion of 1,600 patients (orig-
nally projected 2,200 patients with a minimum follow-up
f one year). The combined end point of all-cause mortality
nd hospitalization was 20% lower in both device groups
ompared to optimized medical therapy. No difference was
oted with respect to the combined primary end point
etween the two device arms, and it was suggested that
dding an ICD had no additional positive effects. However,
significant reduction (36%) in the risk of death was found
n the CRT  ICD group (from 19% to 11%) compared to
tandard therapy whereas CRT resulted only in a non-
ignificant risk of death reduction of 20%. Still, the trial was
ot designed to evaluate the individual benefits from CRT
nd CRT ICD, and currently no data are available on this
igure 10. The incidence of left ventricular (LV) dyssynchrony in patients
V dyssynchrony is expressed as the extent of dyssynchrony between the se
ncidence of LV dyssynchrony was 27% in patients with narrow QRS com
n Bleeker et al. [60]).opic. sConsidering that patients with mild-to-moderate heart
ailure die more often from sudden cardiac death, the
mprovement in NYHA functional class after CRT may be
ssociated with a higher incidence of ventricular arrhyth-
ias, and CRT should always be combined with ICD
ack-up. On the other hand, preliminary data suggest that
he reverse LV remodeling was associated with a reduction
n ventricular arrhythmias (that could be secondary to a
eduction in wall stress) (67). Also, the inducibility of
entricular arrhythmias was less after CRT (68). Still, these
esults were obtained in a small number of patients, and
tudies are needed to provide more insight whether CRT
hould be combined with ICD back-up.
conomic considerations on CRT. There are two general
uestions that can be addressed by medical economic
nalyses: 1) what is the value of a new therapy or technol-
gy, and 2) can we afford it?
To facilitate comparisons among alternative medical
herapies, one can express incremental health benefits either
s additional life years (if the therapy in question increases
ife expectancy) or as additional quality adjusted life years
QALYs) (if quality of life is an important aspect of either
he therapeutic benefit or the underlying disease state being
reated). By general consensus, any therapy that can gener-
te an additional life year for $50,000 or less is judged to be
conomically attractive, while therapies that generate addi-
ional life years for over $100,000 are judged economically
nattractive. As can be easily seen, an expensive therapy
uch as CRT-ICD can be economically attractive as it
roduces a proportionally large improvement in health
enefits. In most cases, the magnitude of health benefits
roduced rather than the price of the therapy is the primary
eterminant of whether the therapy is economically attrac-
ive. Thus, economic value analysis should focus much
ttention on careful definition of what are the incremental
ealth benefits of a particular therapy, along with determin-
ng the long-term net cost.
The second economic question, that of affordability,
narrow QRS complex (120 ms) or wide QRS complex (150 ms). The
and lateral wall. Considering LV dyssynchrony 60 ms as significant, the
s compared to 70% in the patients with wide QRS complex. (Data basedwith
ptum
plex atands apart from the value question. A new therapy may be
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Issues During and After Device Implantation December 20, 2005:2168–82ery economically attractive (that is, a very efficient way to
ncrease health benefits with extra health care dollars), but
till be out of reach for a country or health care system
ecause there are not the extra health care dollars to spend.
Relatively little data exist on the economics of CRT. It is
enerally appreciated that the devices are expensive, with a
ypical U.S. cost for a CRT-ICD device around $30,000. As
reviously noted, the economic questions that need to be
nswered about these devices are: what extra health benefits
expressed in terms of QALYs) does CRT produce, and
hat are its long-term incremental costs, taking into con-
ideration such downstream issues as device replacements,
ead and other complications, as well as heart failure
ospitalizations and emergency department visits prevented.
On the health benefits side, CRT has been reported to
mprove functional capacity (quality of life) and survival (7).
n the cost side, there are reasonable data that CRT reduces
eart failure hospitalizations. In the COMPANION study
10), CRT  ICD and CRT therapy were both associated
ith a 20% reduction in follow-up hospitalization (repre-
enting about $7,700) relative to medical therapy alone. In
he COMPANION trial, CRT  ICD therapy added 0.5
ife years during the course of follow-up relative to medical
herapy alone. The cost effectiveness ratio for CRT-ICD
herapy was $37,000 per life year saved, which is an
conomically attractive result.
As discussed in Part 1 of this review (1), better identifi-
ation of responders to CRT should further improve cost-
ffectiveness of the therapy.
onclusions. Cardiac resynchronization therapy has sig-
ificantly contributed to the treatment of patients with
evere heart failure. To further optimize individual benefit
rom CRT, identification of potential responders is needed.
chocardiography is the technique of choice to identify
esponders before implantation (1). During implantation,
lectroanatomical mapping can be used to identify the site
f latest activation in order to optimize LV lead positioning.
ost patients will have suitable venous anatomy for LV lead
ositioning; however, in the in the absence of suitable veins
n the target region, minimally invasive surgical implanta-
ion should be considered. In patients with AF, AV nodal
blation during pacemaker implantation should be consid-
red, to further optimize response to CRT. Optimization of
acemaker settings after CRT using echocardiography is
mportant; optimization of AV and VV delays has been
emonstrated to further improve benefit from CRT.
The response to CRT extends from immediate benefit
improvement of hemodynamic parameters, MR) to long-
erm benefit (improvement in clinical parameters, systolic
V function, reverse LV remodelling, and further reduction
n MR). In addition, PET studies have shown that cardiac
fficiency is improved after CRT; blood flow does not
mprove after CRT.
Several issues in CRT need further study. These include:
he benefit from CRT in mild-to-moderate heart failure,
he benefit from CRT in patients with narrow QRS
1omplex, and whether ICD back-up is always needed. More
esearch in these fields is needed. Finally, economic consid-
rations are important, and cost-effectiveness of CRT needs
urther study.
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